4077 Background: Curative treatment of liver metastases from colorectal cancer (CRC) relies upon ... more 4077 Background: Curative treatment of liver metastases from colorectal cancer (CRC) relies upon R0 surgery whenever feasible (5-year survival: 40 %). Whether or not addition of adjuvant systemic o...
7348 Background: Gefitinib (Iressa), an inhibitor of the intracellular tyrosine kinase domain, ha... more 7348 Background: Gefitinib (Iressa), an inhibitor of the intracellular tyrosine kinase domain, has demonstrated useful activity in advanced pre-treated NSCLC (IDEAL I/II). Methods: Patients (pts) were treated with gefitinib 250mg/day. Endpoints included time to treatment failure (TTF). Results: 33 patients were assessed: median age (range), 61 (38–82) years; male/female, 21/12; performance status (PS) 1/2, 11/22; advanced disease (III A/IIIB/IV) 1/1/29, 31 pts were treated; median number of prior chemotherapy regimens (range), 3(1–4). 31 patients were treated and evaluable for time to Failure (TTF) according to PS status: 4.8 months (PS 1) and 5 months (PS 2). Median duration of disease control (stable disease and symptom control) was 4.9 months. Median TTF for Patients with bronchoalveolar adenocarcinoma (BAC) and adenocarcinoma (n=18) was 4 months and 3 months for patients with squamous-cell carcinoma and large cell carcinoma (n= 13). One patient treated for BAC with leptomeningeal carcinomatosis was fr...
6078 Background: The EDIFICE study aimed to allow better understanding of population’s adhesion t... more 6078 Background: The EDIFICE study aimed to allow better understanding of population’s adhesion to the tests available for the 4 most frequent cancers: breast, colorectal, prostate and lung. In 1998 the French National Consensus Conference advocated for mass cancer screening (CS) using Hemoccult II. The departments are divided according to the existence or not of an organized program: this screening was organized in 22 departments (3 “scout” started in 1998, 9 “first wave” in 2003 and 12 “second wave” in 2004). Results are reported hereunder. Methods: This first nationwide observational study was carried out in France from January 18th to February 2nd, 2005 among a representative sample of 1504 subjects aged between 40 and 75 years and a representative sample of 600 general practitioners (GPs). Information about participating subjects included socio-demographic characteristics, attitude towards CS, and about GPs’ medical practice regarding CS. Results: Only 25% of the 970 subjects a...
783 Background: In a previous clinical study (ASCO 2000 # 417), we demonstrated a therapeutic syn... more 783 Background: In a previous clinical study (ASCO 2000 # 417), we demonstrated a therapeutic synergism of combined P and V two microtubule poisons with opposite mechanism of action. To optimize efficacy and safety we evaluated a weekly P and biweekly V schedule. METHODS Patients with MBC previously treated with anthracyclines received biweekly V 25 mg/m2 and weekly P 80 mg/m2, 8 weeks course, 2 weeks rest. RESULTS 20 patients (pts) entered the study, with the following characteristics: median age 64 (range 31-74); performance status 0 (12 pts 60%) and 1 (8 pts 40%); postmenopausal 15 (75%); oestrogen receptor negative 14 (70%); pts relapsing within 12 months after anthracyclin-based adjuvant therapy 5 (25%); 13 pts (65%) received one prior chemotherapy for MBC. A total of 189 weeks of treatment could be achieved, with an average of 9.5 weeks (range 1-16). No toxic death was observed. The most frequent adverse event was grade 2 (1 pt 5%), grade 3 (10 pts 50%) and grade 4 (4 pts 20%) neutropenia, including 5 (25%) febrile neutropenia. Haematological support with G-CSF concerned 12 pts (60%). One grade 4 thrombocytopenia was observed. Non haematological toxicity was uncommon: 4 pts (20%) and 1 pt (5%) experienced grade 1-2 and grade 3 peripheral neurotoxicity respectively; 1 pt (5%) experienced grade 4 nausea-vomiting. An objective response was observed in 10/18 evaluable pts (55.5%; 95% confidence interval=32-78) with 1 complete response and a stable disease was observed in 7/18 pts. The median progression-free survival was 174 days (range 12-440). CONCLUSIONS With haematological support, this regimen is feasible in pts with anthracyclin-resistant MBC. Peripheral neurotoxicity is infrequent and manageable. Clinical benefit is promising. No significant financial relationships to disclose.
Study of the antitumour effects of erythropoietin on metastatic renal cell carcinoma. After givin... more Study of the antitumour effects of erythropoietin on metastatic renal cell carcinoma. After giving their informed consent, 20 patients with histologically proven metastatic renal cell carcinoma received subcutaneous recombinant erythropoietin three times a day at a dose of 150 IU/kg when haemoglobin was less than or equal to 12 g/dL or 75 IU/kg when haemoglobin was higher than 12 g/dL. Treatment was continued for a minimum of 8 weeks before reassessment and was continued thereafter, except in the case of progression or excessive toxicity. A staging assessment was performed every 8 weeks and the response was assessed on the basis of WHO criteria. A clinical and laboratory assessment was performed every two months to evaluate toxicity, graded according to the WHO scale. All but one of the patients had received immunotherapy or chemotherapy prior to inclusion in the study. One complete response (> 12 months), one partial response (8 months), two minor responses, 10 cases of stabilis...
We report 2 cases of acute non-lymphocytic leukemia with distinct clinical and karyotypic feature... more We report 2 cases of acute non-lymphocytic leukemia with distinct clinical and karyotypic features shared by therapy-related acute non-lymphocytic leukemia occurring after adjuvant chemotherapy including 5-fluorouracil, doxorubicin and mitomycin C. Our observation suggests a causal relationship between exposure to mitomycin C and the occurrence of acute non-lymphocytic leukemia.
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1997
OBJECTIVES Study of the antitumour effects of erythropoietin on metastatic renal cell carcinoma. ... more OBJECTIVES Study of the antitumour effects of erythropoietin on metastatic renal cell carcinoma. METHODS After giving their informed consent, 20 patients with histologically proven metastatic renal cell carcinoma received subcutaneous recombinant erythropoietin three times a day at a dose of 150 IU/kg when haemoglobin was less than or equal to 12 g/dL or 75 IU/kg when haemoglobin was higher than 12 g/dL. Treatment was continued for a minimum of 8 weeks before reassessment and was continued thereafter, except in the case of progression or excessive toxicity. A staging assessment was performed every 8 weeks and the response was assessed on the basis of WHO criteria. A clinical and laboratory assessment was performed every two months to evaluate toxicity, graded according to the WHO scale. All but one of the patients had received immunotherapy or chemotherapy prior to inclusion in the study. RESULTS One complete response (> 12 months), one partial response (8 months), two minor resp...
L'echographie endo-anale s'est recemment revelee interessante dans l'evaluation des c... more L'echographie endo-anale s'est recemment revelee interessante dans l'evaluation des cancers du canal anal. L'examen est peu invasif et peut etre repete a intervalles reguliers. L'aspect echographique du cancer du canal anal est celui d'une masse hypoechogene, heterogene et mal limitee. L'evaluation echographique de l'extension en profondeur et de l'extension ganglionnaire des cancers du canal anal a une valeur predictive quant au pronostic et a la reponse a la radiotherapie de ces lesions. L'examen est egalement interessant pour evaluer la reponse a la radiotherapie et la detection d'une eventuelle recidive qui est alors a confirmer par des biopsies echo-guidees. L'interpretation des images echographiques du canal anal est cependant difficile apres radiotherapie.
Le cancer du sein, comme toute maladie chronique, modifie progressivement l'etat de sante des... more Le cancer du sein, comme toute maladie chronique, modifie progressivement l'etat de sante des patientes. L'activite physique s'integre dans les soins de support en ameliorant les possibilites fonctionnelles de l'organisme, en optimisant les fonctions principales, cardiovasculaires, osteoarticulaire et neurologique. Elle ameliore l'etat de fatigue et la qualite de vie et semble aussi modifier la survie. Cette activite physique ne s'accompagne pas de complication si elle est realisee de facon medicalement dirigee. Les mecanismes d'action de l'exercice physique sur la maladie cancereuse commencent a etre compris.
4077 Background: Curative treatment of liver metastases from colorectal cancer (CRC) relies upon ... more 4077 Background: Curative treatment of liver metastases from colorectal cancer (CRC) relies upon R0 surgery whenever feasible (5-year survival: 40 %). Whether or not addition of adjuvant systemic o...
7348 Background: Gefitinib (Iressa), an inhibitor of the intracellular tyrosine kinase domain, ha... more 7348 Background: Gefitinib (Iressa), an inhibitor of the intracellular tyrosine kinase domain, has demonstrated useful activity in advanced pre-treated NSCLC (IDEAL I/II). Methods: Patients (pts) were treated with gefitinib 250mg/day. Endpoints included time to treatment failure (TTF). Results: 33 patients were assessed: median age (range), 61 (38–82) years; male/female, 21/12; performance status (PS) 1/2, 11/22; advanced disease (III A/IIIB/IV) 1/1/29, 31 pts were treated; median number of prior chemotherapy regimens (range), 3(1–4). 31 patients were treated and evaluable for time to Failure (TTF) according to PS status: 4.8 months (PS 1) and 5 months (PS 2). Median duration of disease control (stable disease and symptom control) was 4.9 months. Median TTF for Patients with bronchoalveolar adenocarcinoma (BAC) and adenocarcinoma (n=18) was 4 months and 3 months for patients with squamous-cell carcinoma and large cell carcinoma (n= 13). One patient treated for BAC with leptomeningeal carcinomatosis was fr...
6078 Background: The EDIFICE study aimed to allow better understanding of population’s adhesion t... more 6078 Background: The EDIFICE study aimed to allow better understanding of population’s adhesion to the tests available for the 4 most frequent cancers: breast, colorectal, prostate and lung. In 1998 the French National Consensus Conference advocated for mass cancer screening (CS) using Hemoccult II. The departments are divided according to the existence or not of an organized program: this screening was organized in 22 departments (3 “scout” started in 1998, 9 “first wave” in 2003 and 12 “second wave” in 2004). Results are reported hereunder. Methods: This first nationwide observational study was carried out in France from January 18th to February 2nd, 2005 among a representative sample of 1504 subjects aged between 40 and 75 years and a representative sample of 600 general practitioners (GPs). Information about participating subjects included socio-demographic characteristics, attitude towards CS, and about GPs’ medical practice regarding CS. Results: Only 25% of the 970 subjects a...
783 Background: In a previous clinical study (ASCO 2000 # 417), we demonstrated a therapeutic syn... more 783 Background: In a previous clinical study (ASCO 2000 # 417), we demonstrated a therapeutic synergism of combined P and V two microtubule poisons with opposite mechanism of action. To optimize efficacy and safety we evaluated a weekly P and biweekly V schedule. METHODS Patients with MBC previously treated with anthracyclines received biweekly V 25 mg/m2 and weekly P 80 mg/m2, 8 weeks course, 2 weeks rest. RESULTS 20 patients (pts) entered the study, with the following characteristics: median age 64 (range 31-74); performance status 0 (12 pts 60%) and 1 (8 pts 40%); postmenopausal 15 (75%); oestrogen receptor negative 14 (70%); pts relapsing within 12 months after anthracyclin-based adjuvant therapy 5 (25%); 13 pts (65%) received one prior chemotherapy for MBC. A total of 189 weeks of treatment could be achieved, with an average of 9.5 weeks (range 1-16). No toxic death was observed. The most frequent adverse event was grade 2 (1 pt 5%), grade 3 (10 pts 50%) and grade 4 (4 pts 20%) neutropenia, including 5 (25%) febrile neutropenia. Haematological support with G-CSF concerned 12 pts (60%). One grade 4 thrombocytopenia was observed. Non haematological toxicity was uncommon: 4 pts (20%) and 1 pt (5%) experienced grade 1-2 and grade 3 peripheral neurotoxicity respectively; 1 pt (5%) experienced grade 4 nausea-vomiting. An objective response was observed in 10/18 evaluable pts (55.5%; 95% confidence interval=32-78) with 1 complete response and a stable disease was observed in 7/18 pts. The median progression-free survival was 174 days (range 12-440). CONCLUSIONS With haematological support, this regimen is feasible in pts with anthracyclin-resistant MBC. Peripheral neurotoxicity is infrequent and manageable. Clinical benefit is promising. No significant financial relationships to disclose.
Study of the antitumour effects of erythropoietin on metastatic renal cell carcinoma. After givin... more Study of the antitumour effects of erythropoietin on metastatic renal cell carcinoma. After giving their informed consent, 20 patients with histologically proven metastatic renal cell carcinoma received subcutaneous recombinant erythropoietin three times a day at a dose of 150 IU/kg when haemoglobin was less than or equal to 12 g/dL or 75 IU/kg when haemoglobin was higher than 12 g/dL. Treatment was continued for a minimum of 8 weeks before reassessment and was continued thereafter, except in the case of progression or excessive toxicity. A staging assessment was performed every 8 weeks and the response was assessed on the basis of WHO criteria. A clinical and laboratory assessment was performed every two months to evaluate toxicity, graded according to the WHO scale. All but one of the patients had received immunotherapy or chemotherapy prior to inclusion in the study. One complete response (> 12 months), one partial response (8 months), two minor responses, 10 cases of stabilis...
We report 2 cases of acute non-lymphocytic leukemia with distinct clinical and karyotypic feature... more We report 2 cases of acute non-lymphocytic leukemia with distinct clinical and karyotypic features shared by therapy-related acute non-lymphocytic leukemia occurring after adjuvant chemotherapy including 5-fluorouracil, doxorubicin and mitomycin C. Our observation suggests a causal relationship between exposure to mitomycin C and the occurrence of acute non-lymphocytic leukemia.
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1997
OBJECTIVES Study of the antitumour effects of erythropoietin on metastatic renal cell carcinoma. ... more OBJECTIVES Study of the antitumour effects of erythropoietin on metastatic renal cell carcinoma. METHODS After giving their informed consent, 20 patients with histologically proven metastatic renal cell carcinoma received subcutaneous recombinant erythropoietin three times a day at a dose of 150 IU/kg when haemoglobin was less than or equal to 12 g/dL or 75 IU/kg when haemoglobin was higher than 12 g/dL. Treatment was continued for a minimum of 8 weeks before reassessment and was continued thereafter, except in the case of progression or excessive toxicity. A staging assessment was performed every 8 weeks and the response was assessed on the basis of WHO criteria. A clinical and laboratory assessment was performed every two months to evaluate toxicity, graded according to the WHO scale. All but one of the patients had received immunotherapy or chemotherapy prior to inclusion in the study. RESULTS One complete response (> 12 months), one partial response (8 months), two minor resp...
L'echographie endo-anale s'est recemment revelee interessante dans l'evaluation des c... more L'echographie endo-anale s'est recemment revelee interessante dans l'evaluation des cancers du canal anal. L'examen est peu invasif et peut etre repete a intervalles reguliers. L'aspect echographique du cancer du canal anal est celui d'une masse hypoechogene, heterogene et mal limitee. L'evaluation echographique de l'extension en profondeur et de l'extension ganglionnaire des cancers du canal anal a une valeur predictive quant au pronostic et a la reponse a la radiotherapie de ces lesions. L'examen est egalement interessant pour evaluer la reponse a la radiotherapie et la detection d'une eventuelle recidive qui est alors a confirmer par des biopsies echo-guidees. L'interpretation des images echographiques du canal anal est cependant difficile apres radiotherapie.
Le cancer du sein, comme toute maladie chronique, modifie progressivement l'etat de sante des... more Le cancer du sein, comme toute maladie chronique, modifie progressivement l'etat de sante des patientes. L'activite physique s'integre dans les soins de support en ameliorant les possibilites fonctionnelles de l'organisme, en optimisant les fonctions principales, cardiovasculaires, osteoarticulaire et neurologique. Elle ameliore l'etat de fatigue et la qualite de vie et semble aussi modifier la survie. Cette activite physique ne s'accompagne pas de complication si elle est realisee de facon medicalement dirigee. Les mecanismes d'action de l'exercice physique sur la maladie cancereuse commencent a etre compris.
Uploads
Papers by T. Bouillet